MUMBAI: Glenmark Pharmaceuticals Ltd (Glenmark), an innovation-driven global pharmaceutical company, today announced its financial results for the fourth quarter ended March 31, 2022.
For the fourth quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs 30,191 mn as against Rs 28,599 mn, recording an increase of 5.6 per cent YoY. Adjusted EBITDA [i] was Rs 5,022 mn in the quarter ended March 31, , with margins of 16.6 per cent. Reported EBITDA was Rs 4,634 mn, as compared to Rs 5,234 mn in the previous corresponding quarter with margins of 15.3 per cent.
Adjusted Net Profit (PAT) [ii] was at Rs. 2,939 Mn for the quarter ended March 31, 2022. Reported PAT was at Rs 1,726 mn for the quarter ended March 31, as compared to Rs 2,340 mn in the previous corresponding quarter.
Glenmark’s consolidated revenue was at Rs 1,23,049 mn as against Rs 1,09,439 mn, recording an increase of 12.4 per centover the previous corresponding period. Adjusted EBITDA[iii] for the fiscal year stood at Rs 23,591 mn. Reported EBITDA stood at Rs 23,203 mn as against Rs 20,844 mn in the previous corresponding period.
Net Profit (PAT) was at Rs 9,936 mn for the year, as against Rs 9,701 mn. in the previous year. Earnings Per Share (EPS) is at Rs 33.4 as compared to Rs. 34.4 YoY basis.
“We delivered consistent performance throughout the year and achieved our key objectives, despite challenging global macro environment. We were able to successfully list Glenmark Lifesciences on the Indian bourses. The out-licensing deal for ISB 880 with Almirall and USFDA approval for Ryaltris, further established us as the leading innovation-driven pharma company in the country.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.
He added,”We are confident of growing our business with continuous emphasis on innovation, sustainability, and prioritising free cash generation for additional debt reduction.” (ANI/PRNewswire)